|
A phase III, multicenter study to assess the diagnostic performance and clinical impact of 18F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR). |
|
|
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; Bayer; Blue Earth Diagnostics; Endocyte; Tokai Pharmaceuticals; Tolmar |
Speakers' Bureau - ORIC Pharmaceuticals |
Research Funding - Bayer (Inst); Corcept Therapeutics (Inst); Endocyte (Inst); Progenics (Inst); Roche/Genentech (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Bayer; Endocyte |
|
|
Honoraria - Abbvie; Amgen; Astellas Pharma; Bayer; Genzyme; Janssen; Pfizer; Sanofi |
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Genzyme; Janssen; Pfizer; Progenics; Sanofi |
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Sanofi |
Research Funding - Astellas Medivation; AstraZeneca; Janssen; Merck (Inst); Progenics (Inst); Sanofi |
Patents, Royalties, Other Intellectual Property - Universite Laval |
|
|
Research Funding - Progenics (Inst) |
|
|
Research Funding - Progenics (Inst) |
|
|
Research Funding - Progenics (Inst) |
|
|
Employment - Tower Urology |
Leadership - Precision Ambulatory Surgery Center |
Stock and Other Ownership Interests - Intuitive Surgical; UroGen pharma |
|
Consulting or Advisory Role - Exosome Diagnostics |
Speakers' Bureau - Abbvie |
Research Funding - Progenics (Inst) |
|
|
Research Funding - Accuray (Inst); Progenics (Inst) |
|
|
Honoraria - Intuitive Surgical |
Consulting or Advisory Role - Nutcracker Therapeutics, Inc. |
|
|
|
Stock and Other Ownership Interests - Progenics |
|
|
|
Stock and Other Ownership Interests - Progenics |
|
|
|
|
Stock and Other Ownership Interests - Progenics |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Blue Earth Diagnostics; BTG; Curium Pharma; GE Healthcare; GlaxoSmithKline; ImaginAb; Progenics |
Research Funding - Blue Earth Diagnostics; ImaginAb; Progenics |
Travel, Accommodations, Expenses - Siemens (I) |